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gynaecological malignancies in Qatar.
followed by endometrial cancer 
(16.0%).
In conclusion, gynecological 
malignancies are common in Saudi 
Arabia. Further study is needed to 
assess the risk factors for ovarian 
and endometrial cancer in Saudi 
Arabia with more specification 
about histological types. The need 
for national screening program for 
cervical cancer is raised and we need 
to improve our reporting system for 
cancer cases.
These findings provide an ad-
equate foundation for planning of 
gynecological cancer education, 
screening programs and resource al-
location in Saudi Arabia.
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Bone mineral density in 
ex-thalassemic pediatric 
patients
To the Editor: In b-thalassemia 
major, extreme bone marrow hyper-
plasia, bone expansion, extramed-
ullary hematopoiesis and growth 
retardation are present due to inef-
fective erythropoiesis.1 Bone de-
formity, delayed bone age, growth 
failure, rickets, scoliosis, spinal de-
formities, nerve compression, osteo-
penia and osteoporosis,2 are some 
of bone disorders that thalassemic 
patients suffer from. 
Even in well-treated patients, 
osteoporosis and low bone mass are 
common problem that could cause 
pathologic fracture and further 
complications in the course of the 
disease. Allogeneic hematopoietic 
stem cell transplantation (HSCT) 
has emerged as a cornerstone in the 
development of cell-based therapies 
in these patients that may provide 
them with disease-free survival.3 
The risks associated with HSCT 
are substantial and should be con-
sidered. Low bone density is one of 
the common problems in HSCT-
treated thalassemic patients. It can 
be caused by various factors in-
cluding gonadal failure, prolonged 
immobility, decreased osteopro-
genitor cells, use of conditioning 
regimens, vitamin D deficiency, sec-
ondary hyperparathyroidism, and 
cyclosporine-corticosteroid ther-
apy for graft-versus-host disease 
(GVHD).4 After Italy, Iran has the 
largest population of transplanted 
thalassemic patients. In this regard, 
we aimed to monitor the bone sta-
tus of HSC transplanted patients 
before and after transplantation.5
In our center, the policy is to 
transplant all transfusion-depen-
dent beta-thalassemia major pa-
tients who had HLA-identical 
related donors, regardless of their 
disease severity. We enrolled 20 
patients from three classes of thal-
assemia who were candidates for 
HSCT in this study. The mean 
(SD) age of patients was 7.4 (3.8) 
years and the female:male ratio 
was 1:1. The bone mineral density 
(BMD) of participants was tested 
at baseline (before transplanta-
tion), and at 6 and 12 months 
post-transplant using a Norland 
XR-46 device (Norland Corp, Fort 
Arkinson, WI, USA). Prophylaxis 
for GVHD included corticosteroid 
and cyclosporine. All the 20 pa-
tients in the study who completed 
the three phases of the study were 
free from any transfusion for at least 
1 year after HSCT. After discharge, 
patients were followed in our post-
HSCT clinic weekly for the first 
month, then every two weeks until 
day 100, and thereafter according to 
the condition of each patient until 
one year.
The term “low bone mineral 
density for age” is a criterion for 
low bone mass in children, and is 
described as a child with a z score 
<-2. None of our patients met 
this criteria, either before or after 
transplant. No significant change in 
BMD was detected after transplant 
(both 6 and 12 months follow-up) 
in the three groups of our patients. 
Indeed, no remarkable association 
between corticosteroid usage and 
BMD was observed. In ex-thalasse-
letters
Hematol Oncol Stem Cell Ther 5(1)     First Quarter 2012 hemoncstem.edmgr.com 71
mic patients BMD changes, before 
and after transplant, were not sig-
nificant. Class 3 thalassemia had no 
negative effect on BMD. 
In a long-term follow-up of 
HSCT patients, Schulte et al re-
ported a maximum decrease of 
BMD in femoral neck 24 months 
post-transplantation.6 Based on this 
observation, it is presumable that 
in our study, significant changes 
in BMD would be detected if the 
patients were followed for longer 
period of time. It is noteworthy to 
state that even at the beginning of 
the study, none of our patients were 
osteopenic or categorized as hav-
ing “low bone mineral density for 
age” (z score <-2) which might also 
contribute to not finding significant 
changes over time in bone status af-
ter transplantation. 
In this study, we did not observe 
a correlation between corticoste-
roid treatment and BMD. Many 
investigators, including D’Souza et 
al4 and Schulte et al,6 have shown a 
significant diminishing effect of cor-
ticosteroids on BMD among trans-
planted patients. However, unlike 
our study, their study population 
did not always include pediatric 
thalassemic subjects. On the other 
hand, consistent with our study, 
Daniels and colleagues7 found no 
significant relationship between 
glucocorticoid use and BMD in pe-
diatric-transplanted patients. Lack 
of association between corticoste-
roids and cyclosporine exposure 
and BMD in our patients might, or 
at least partially, be also related to 
the small sample size of this study. 
Moreover, it has been suggested that 
simultaneous administration of cy-
closporine and glucocorticoids may 
compensate the individual effect 
of each agent on bone turnover. In 
the initial post-transplant period, 
when doses of glucocorticoids are 
high, the steroid effect may cause a 
low bone turnover state. However, 
a later reduction in the dose of glu-
cocoticoids may “reveal” the high 
turnover state induced by cyclospo-
rines.8 
In conclusion, in our study, 
HSCT in pediatric thalassemic pa-
tients did not produce any signifi-
cant positive or negative effect on 
BMD. Though none of our patients 
had a pre-transplant z score less 
than -2, none of them were diag-
nosed as having “low bone mineral 
density for age” after transplanta-
tion. Future studies with larger 
sample sizes and longer monitoring 
periods are recommended.
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